Linked Life Data

17939763

Source:http://linkedlifedata.com/resource/pubmed/id/17939763

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2007-10-17
pubmed:abstractText
Donepezil is the most widely prescribed of the cholinesterase inhibitors that has been licensed for the treatment of mild-to-moderate Alzheimer's disease. Evidence from a number of clinical trials suggests that it improves cognitive performance and stabilizes the functional abilities in people with mild-to-moderate Alzheimer's disease. Donepezil increases the amount of the neurotransmitter acetylcholine in the brain, the deficit of which is thought to play a major role in the clinical presentation of Alzheimer's disease. Studies show good safety and long-term tolerability. In addition, donepezil's pharmacokinetic properties make it convenient to prescribe. There are a number of newer drug therapies in various stages of pharmacological development, but donepezil should continue to play a major role in the treatment of Alzheimer's disease for the next few years.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1744-8360
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1243-9
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Donepezil for Alzheimer's disease.
pubmed:affiliation
Department of Old Age Psychiatry, Second Floor, Education and Resource Centre, Wythenshawe Hopsital, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK. bobenb@doctors.org.uk
pubmed:publicationType
Journal Article, Review